146 related articles for article (PubMed ID: 1917159)
1. Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine.
Momparler RL; Bouffard DY; Momparler LF; Marquet J; Zittoun J; Marie JP; Zittoun R
Int J Cancer; 1991 Oct; 49(4):573-6. PubMed ID: 1917159
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
Momparler RL; Momparler LF
Cancer Chemother Pharmacol; 1989; 25(1):51-4. PubMed ID: 2480188
[TBL] [Abstract][Full Text] [Related]
3. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
4. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
Raynal NJ; Momparler LF; Rivard GE; Momparler RL
Leuk Res; 2011 Jan; 35(1):110-8. PubMed ID: 20510451
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells.
Bhalla K; Birkhofer M; Arlin Z; Grant S; Lutzky J; Graham G
Leukemia; 1988 Dec; 2(12):810-3. PubMed ID: 3264363
[TBL] [Abstract][Full Text] [Related]
7. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
[TBL] [Abstract][Full Text] [Related]
9. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Fritzer-Szekeres M; Salamon A; Grusch M; Horvath Z; Höchtl T; Steinbrugger R; Jäger W; Krupitza G; Elford HL; Szekeres T
Biochem Pharmacol; 2002 Aug; 64(3):481-5. PubMed ID: 12147300
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
Bhalla K; Birkhofer M; Arlin Z; Grant S; Lutzky J; Safah H; Graham G
Exp Hematol; 1991 Aug; 19(7):669-73. PubMed ID: 1893953
[TBL] [Abstract][Full Text] [Related]
12. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
White JC; Hines LH
Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615
[TBL] [Abstract][Full Text] [Related]
13. A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines.
Zittoun J; Marquet J; David JC; Maniey D; Zittoun R
Cancer Chemother Pharmacol; 1989; 24(4):251-5. PubMed ID: 2752506
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
Tanaka M; Kimura K; Yoshida S
Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
Momparler RL; Onetto-Pothier N; Momparler LF
Leuk Res; 1990; 14(9):755-60. PubMed ID: 1700231
[TBL] [Abstract][Full Text] [Related]
16. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
17. Ara-C metabolism: implications for drug resistance and drug interactions.
Chabner BA; Hande KR; Drake JC
Bull Cancer; 1979; 66(1):89-92. PubMed ID: 420952
[TBL] [Abstract][Full Text] [Related]
18. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
Lauzon GJ; Paran JH; Paterson AR
Cancer Res; 1978 Jun; 38(6):1723-9. PubMed ID: 274174
[TBL] [Abstract][Full Text] [Related]
19. Increased accumulation of cytosine arabinoside in human leukemic cells and enhancement of its cell-killing activity by uridine.
Takahashi I; Hayashi N; Nakamura T; Matuzaki T; Murase T; Osada K; Takeuchi M; Ueki Y; Nakada H; Yorimitsu S
Acta Med Okayama; 1990 Dec; 44(6):329-31. PubMed ID: 2075831
[TBL] [Abstract][Full Text] [Related]
20. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
Nishi R; Yamauchi T; Negoro E; Takemura H; Ueda T
Cancer Sci; 2013 Apr; 104(4):502-7. PubMed ID: 23320492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
